Zachary Zimmerman had been appointed as director of business development at Regulus Therapeutics, a Carlsbad, Calif.-based company that develops microRNA drugs.
Prior to joining Regulus, he spent five years in the business development group of Alnylam Pharmaceuticals. Before that, he was a senior research analyst for IDC's Life Sciences practice with a focus on disruptive technologies, and prior to that, a lead scientist at 454 Life Sciences.
Zimmerman holds a PhD in molecular, cellular, and developmental biology from the University of California, Santa Cruz.